For a complete list of publications, please visit Dr. Lee's NCBI Bibliography.

Papers since 2010 from the Chronic GVHD Consortium (from a total of 473)

1.       Kitko CL, Arora M, DeFilipp Z, Abu Zaid M, Di Stasi A, Radojcic V, Betts CB, Coussens LM, Meyers ML, Qamoos H, Ordentlich P, Kumar V, Quaranto C, Schmitt A, Gu Y, Blazar BR, Wang TP, Salhotra A, Pusic I, Jagasia M, Lee SJ. Axatilimab for chronic graft-versus-host disease after failure of at least 2 prior systemic therapies: results of a phase 1/2 study. Clin Oncol 2022, in press [original work]

2.       Manjappa S, Phi HQ, Lee LW, Onstad L, Gill DB, Connelly-Smith L, Krakow EF, Flowers ME, Carpenter PA, Hill JA, Lee SJ. Humoral and cellular immune response to Covid-10 vaccination in patients with chronic graft-versus-host disease on immunosuppression. Transplant Cell Ther 2022, 11: 784.e1-784.e9 [original work]

3.       Lee SJ, Cutler C, Blazar BR, Tu A, Yang Z, Pavletic SZ. Correlation of patient-reported outcomes with clinical organ responses: data from the belumosudil chronic graft-versus-host disease studies. Transplant Cell Ther 2022; 10: 700.e1-700.e6 [original work]

4.       Chen GL, Onstad L, Martin PJ, Carpenter P, Pidala J, Arai S, Cutler C, Hamilton BK, Lee SJ, Arora M. Durable discontinuation of systemic therapy in patients affected by chronic graft-versus-host disease. Haematologica. in press [original work]

5.       Pidala J, Onstad L, Martin P, Hamilton B, Cutler C, Kitko C, Carpenter P, Chen G, Arora M, Flowers M, Arai S, Alousi A, White J, Jacobsohn D, Pusic I, Lee SJ. Initial therapy of chronic graft-vs.-host disease: Analysis of practice variation and failure-free survival. Blood Adv 2021; 5: 4549-4559 [original work]

6.       Cutler CS, Lee SJ, Arai S, Rotta M, Zoghi B, Lazaryan A, Ramakrishnan A, DeFilipp Z, Salhotra A, Chai-Ho W, Mehta RS, Wang T, Arora M, Pusic I, Saad A, Shah NN, Abhyankar S, Bachier C, Galvin J, Im A, Langston A, Liesveld JL, Juckett M, Logan A, Schachter L, Alavi A, Howard DS, Waksal H, Ryan J, Eiznhamer D, Aggarwal SK, Ieyoub J, Schueller O, Green L, Yang Z, Krenz H, Jagasia M, Blazar BR, Pavletic SZ. Belumosudil for chronic graft-versus-host disease (cGVHD) after 2 or more prior lines of therapy: The ROCKstar study. Blood 2021; 138: 2278-2289. [original work]

7.       DeFilipp Z, Alousi AM, Pidala JA, Carpenter PA, Onstad LE, Arai S, Arora M, Cutler CS, Flowers MED, Kitko CL, Chen GL, Lee SJ, Hamilton BK. Nonrelapse mortality among patients diagnosed with chronic GVHD: An updated analysis from the Chronic GVHD Consortium. Blood Adv 2021; 5: 4278-4282 [original work]

8.       Inamoto Y, Martin PJ, Onstad LE, Cheng GS, Williams KM, Pusic I, Ho VT, Arora M, Pidala J, Flowers MED, Gooley TA, Lawler RL, Hansen JA, Lee SJ. Relevance of plasma matrix metalloproteinase-9 for bronchiolitis obliterans syndrome after allogeneic hematopoietic cell transplantation. Transplant Cell Ther 2021; 27: 759e1-759e8 [original work]

9.       Jagasia M, Lazaryan A, Bachier CR, Salhotra A, Weisdorf DJ, Zoghi B, Essell J, Green L, Schueller O, Patel J, Zanin-Zhorov A, Weiss JM, Yang Z, Eiznhamer D, Aggarwal SK, Blazar BR, Lee SJ. ROCK2 inhibition with belumosudil (KD025) for the treatment of chronic graft-versus-host disease. J Clin Oncol 2021; 39: 1888-1898 [original work]

10.    Zeiser R, Polverelli N, Ram R, Hashmi SK, Chakraverty R, Middeke JM, Musso M, Giebel S, Uzay A, Langmuir P, Hollaender N, Gowda M, Stefanelli T, Lee SJ, Teshima T, Locatelli F. Ruxolitinib for glucocorticoid-refractory chronic graft-versus-host disease. N Eng J Med 2021; 385: 228-238 [original work]

11.    Pidala J, Bhatt VR, Hamilton B, Pusic I, Wood WA, Onstad L, Hall A, Storer B, Lee SJ. Ixazomib for treatment of refractory chronic graft vs. host disease: A Chronic GVHD Consortium phase II trial: Ixazomib for chronic GVHD treatment; Biol Blood Marrow Transplant 2020; 26: 1612-1619 [original work]

12.    The C, Onstad L, Lee SJ. Reliability and validity of the modified 7-day Lee Chronic Graft-versus-Host Disease Symptom Scale. Biol Blood Marrow Transplant 2020; 26: 562-567 [original work]

13.    Hamilton BK, Storer BE, Wood WA, Pidala JA, Cutler CS, Martin PJ, Chen G, Flowers ME, Lee SJ. Disability related to chronic graft-versus-host disease. Biol Blood Marrow Transplant 2020; 26: 772-777. [original work]

14.    Pidala J, Jaglowski S, Im A, Chen G, Onstad L, Storer B, Kurukulasuriya C, Lee SJ. Carfilzomib for treatment of refractory chronic graft-vs.-host disease: A Chronic GVHD Consortium pilot phase II trial. Biol Blood Marrow Transplant 2020; 26: 278-284. [original work]

15.    Inamoto Y, Lee SJ, Onstad LE, Flowers MED, Hamilton BK, Jagasia MH, Martin PJ, Pavletic SZ, Pidala JA, Pusic I, Vogelsang GB, Wolff D, Carpenter PA. Refined National Institutes of Health response algorithm for chronic graft-versus-host disease in joints and fascia. Blood Adv 2020; 14: 40-46. [original work]

16.    Pidala JA, Hamilton BK, Martin PJ, Onstad L, Storer BE, Palmer J, Alousi A, Cutler C, Jagasia MH, Chen GL, Arora M, Flowers ME, Lee SJ. The chronic graft-vs.-host disease failure-free survival (cGVHD-FFS) index. Bio Blood Marrow Transplant 2019; 25: 2468-2473 [original work]

17.    Martin PJ, Storer BE, Palmer J, Jagasia MH, Chen GL, Broady R, Arora M, Pidala JA, Hamilton BK, Lee SJ. Organ changes associated with provider-assessed responses in patients with chronic graft-versus-host disease. Biol Blood Marrow Transplant 2019; 25: 1869-1874 [original work]

18.    Khera N, Hamilton BK, Pidala JA, Wood WA, Wu V, Voutsinas J, Onstad L, Alousi AM, Broady R, Chen GL, Arora M, Cutler C, Flowers ME, Ganetsky A, Jagasia M, McCarthy PL, Sarantopoulos S, Abel GA, Majhail NS, Lee SJ. Employment, insurance, and financial experiences of patients with chronic graft-versus-host disease in North America. Biol Blood Marrow Transplant 2019; 25: 599-605 [original work]

19.    Gandelman JS, Zic J, Dewan AK, Lee SJ, Flowers M, Cutler C, Pidala J, Chen H, Jagasia MH, Tkaczyk ER. The anatomic distribution of skin involvement in patients with incident chronic graft-versus-host disease. Biol Blood Marrow Transplant 2019; 25: 279-286. [original work]

20.    Gandelman JS, Byrne MT, Mistry AM, Polikowsky HG, Diggins KE, Chen H, Lee SJ, Arora M, Cutler C, Flowers M, Pidala J, Irish JM, Jagasia MH. Machine learning reveals chronic graft-versus-host disease phenotypes and stratifies survival after stem cell transplant for hematologic malignancies. Haematologica 2019; 104: 189-196. [original work]

21.    El-Jawahri A, Pidala J, Khera N, Wood WA, Cutler C, Arora M, Carpenter PA, Palmer J, Flowers M, Weisdorf D, Jagasia M, Chen YB, Lee SJ. Impact of psychological distress on quality of life, functional status, and survival in patients with chronic graft-versus-host disease. Biol Blood Marrow Transplant 2018: 2285-2292. [original work]

22.    Lee SJ, Onstad L, Chow EJ, Shaw BE, Jim HSL, Syrjala KL, Baker KS, Buckley S, Flowers ME. Patient-reported outcomes and health status associated with chronic GVHD. Haematologica 2018, 103: 1535-1541. [original work]

23.    Lee SJ, Hamilton BK, Pidala J, Alousi A, Kurukulasuriya C, Onstad L, Jagasia M, Chen G, Cutler C, Broady R, Arora M, Arai S, Sarantopoulos S, Flowers ME. Design and patient characteristics of the Chronic Graft-versus-Host Disease Response Measures Validation Study. Biol Blood Marrow Transplant 2018; 24: 1727-1732. [review]

24.    Deegan AJ, Talebi-Liasi F, Song S, Li Y, Xu J, Men S, Shinohara MM, Flowers ME, Lee SJ, Wang RK. Optical coherence tomography angiography of normal skin and inflammatory dermatologic conditions, Lasers Surg Med 2018; 50: 183-193. [original work]

25.    Lee SJ, Nguyen TD, Onstad L, Bar M, Krakow EF, Salit RB, Carpenter PA, Rodrigues M, Hall AM, Storer BE, Martin PJ, Flowers ME. Success of immunosuppressive treatments in patients with chronic graft-versus-host disease. Biol Blood Marrow Transplant 2018; 24: 555-562. [original work]

26.    Hamilton BK, Rybicki L, Arai S, Arora M, Cutler C, Flowers ME, Jagasia M, Martin PJ, Palmer J, Pidala J, Majhail N, Lee SJ, Khera N. Association of socioeconomic status with chronic graft-versus-host disease outcomes. Biol Blood Marrow Transplant 2018: 24: 393-399. [original work]

27.    Inamoto Y, Martin PJ, Paczesny S, Tebellini L, Momin AA, Mumaw CL, Flowers MED, Lee SJ, Carpenter PA, Storer BE, Hanash S, Hansen JA. Association of plasma CD163 concentration with de novo-onset chronic graft-versus-host disease. Bio Blood Marrow Transplant 2017; 23: 1250-1256. [original work]

28.    Pidala J, Sigdel T, Wang A, Hsieh S, Inamoto Y, Martin P, Flowers M, Lee SJ, Sarwal M. A combined biomarker and clinical panel for chronic graft vs. host disease diagnosis. J Pathol Clin res 2016; 29: 3-16. [original work]

29.    Yu J, Storer BE, Kushekhar K, Zaid MA, Zhang Q, Gafken PR, Ogata Y, Martin PJ, Flowers ME, Hansen JA, Arora M, Cutler C, Jagasia M, Pidala J, Hamilton BK, Chen GL, Pusic I, Lee SJ, Paczesny S. Biomarker panel for chronic graft-versus-host disease. J Clin Oncol 2016; 34: 2583-2590. [original work]

30.    Vasconcellos de Souza C, Vigorito AC, Miranda EC, Garcia C, Colturato VAR, Mauad MA, Moreira MCR, Bouzas LF, Lermontov S, Hamerschlak N, Rodrigues M, Barros JC, Chiattone R, Lee SJ, Flowers ME. Translation, cross-cultural adaptation and validation of the Lee Chronic Graft-versus-Host Disease (GVHD) Symptom Scale in a Brazilian Population. Biol Blood Marrow Transplant 2016; 22: 1313-1318. [original work]

31.    Merkel EC, Mitchell SA, Lee SJ. Content validity of the Lee chronic graft-versus-host disease symptom scale as assessed by cognitive interviews. Biol Blood Marrow Transplant 2016; 22: 752-758. [original work]

32.    Arora M, Cutler CS, Jagasia MH, Pidala J, Chai X, Martin PJ, Flowers ME, Inamoto Y, Chen GL, Wood WA, Khera N, Palmer J, Duong H, Arai S, Mayer S, Pusic I, Lee SJ. Late acute and chronic graft-versus-host disease after allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transplant 2016; 22: 449-455. [original work]

33.    Palmer J, Chai X, Pidala J, Inamoto Y, Martin PJ, Storer B, Pusic I, Flowers ME, Arora M, Pavletic SZ, Lee SJ. Predictors of survival, non-relapse mortality and failure-free survival in patients treated for chronic graft-versus-host disease. Blood 2016; 127: 160-166.  [original work]

34.    Arai S, Pidala J, Pusic I, Chai X, Jaglowski S, Khera N, Palmer J, Chen GL, Jagasia MH, Mayer SA, Wood WA, Green M, Hyun TS, Inamoto Y, Storer BE, Miklos DB, Shulman HM, Martin PJ, Sarantopoulos S, Lee SJ, Flowers ME. A randomized phase II crossover study of imatinib or rituximab for cutaneous sclerosis after hematopoietic cell transplantation. Clin Cancer Res 2016; 22: 319-327. [original work]

35.    Inamoto Y, Sun YC, Flowers ME, Carpenter PA, Martin PJ, Li P, Wang R, Chai X, Storer BE, Shen TT, Lee SJ. Bandage soft contact lenses for ocular graft-versus-host disease. Biol Blood Marrow Transplant 2015, 21: 2002-2007. [original work]

36.    Palmer J, Chai X, Martin PJ, Weisdorf D, Inamoto Y, Pidala J, Jagasia M, Pavletic S, Cutler C, Vogelsang G, Arai S, Flowers ME, Lee SJ. Failure-free survival in a prospective cohort of patients with chronic graft-versus-host disease. Haematologica 2015; 100: 690-695. [original work]

37.    Inamoto Y, Martin PJ, Storer BE, Palmer J, Weisdorf DJ, Pidala J, Flowers ME, Arora M, Jagasia M, Arai S, Chai X, Pavletic SZ, Vogelsang GB, Lee SJ. Association of severity of organ involvement with mortality and recurrent malignancy in patients with chronic graft-versus-host disease. Haematologica 2014; 99: 1618-1623. [original work]

38.    El-Jawahri A, Pidala J, Inamoto Y, Chai X, Khera N, Wood WA, Cutler C, Arora M, Carpenter PA, Palmer J, Flowers M, Weisdorf D, Pavletic S, Jaglowski S, Jagasia M, Lee SJ, Chen YB. Impact of age on quality of life, functional status and survival in patients with chronic graft-versus-host disease. Biol Blood Marrow Transplant 2014; 20: 1341-8. [original work]

39.    Kitko CL, Levine JE, Storer BE, Chai X, Fox DA, Braun TM, Couriel DR, Martin PJ, Flowers ME, Hansen JA, Chang L, Conlon M, Fiema BJ, Morgan R, Pongtornpipat P, Lamiman K, Ferrara JL, Lee SJ, Paczesny S. Plasma CXCL9 elevations correlate with chronic GVHD diagnosis. Blood 2014; 123: 786-793. [original work]

40.    Palmer J, Williams K, Inamoto Y, Chai X, Martin PJ, Tomas LS, Cutler C, Weisdorf D, Kurland BF, Carpenter PA, Pidala J, Pavletic SZ, Wood W, Jacobsohn D, Arai S, Arora M, Jagasia M, Vogelsang GB, Lee SJ. Pulmonary symptoms measured by the National Institutes of Health lung score predict overall survival, nonrelapse mortality and patient-reported outcomes in chronic graft-versus-host disease. Biol Blood Marrow Transplant 2014; 20: 337-344. [original work]

41.    Inamoto Y, Pidala J, Chai X, Kurland BF, Weisdorf D, Flowers ME, Palmer J, Arai S, Jacobsohn D, Cutler C, Jagasia M, Goldberg JD, Martin PJ, Pavletic SZ, Vogelsang GB, Lee SJ, Carpenter PA, Chronic GVHD Consortium. Assessment of joints and fascia manifestations in chronic graft-versus-host disease. Arthritis Rheumatol 2014; 66: 1044-1052. [original work]

42.    Pidala J, Sarwal M, Roedder S, Lee SJ. Biologic markers of chronic GVHD. Bone Marrow Transplant 2014; 49: 324-331. [review]

43.    Wood WA, Chai X, Weisdorf D, Martin PJ, Cutler C, Inamoto Y, Wolff D, Pavletic SZ, Pidala J, Palmer JM, Arora M, Arai S, Jagasia M, Storer B, Lee SJ, Mitchell S. Comorbidity burden in patients with chronic GVHD. Bone Marrow Transplant 2013; 48: 1429-1436. [original work]

44.    Pidala J, Chai X, Martin P, Inamoto Y, Cutler C, Palmer J, Weisdorf D, Pavletic S, Arora M, Jagasia M, Jacobsohn D, Lee SJ. Hand grip strength and 2 minute walk test in chronic graft-versus-host disease assessment: an analysis from the Chronic GVHD Consortium. Biol Blood Marrow Transplant 2013; 19: 967-972. [original work]

45.    Pidala J, Chai X, Kurland BF, Inamoto Y, Flowers MED, Palmer J, Khera N, Jagasia M, Cutler C, Arora M, Vogelsang G, Lee SJ. Analysis of gastrointestinal and hepatic chronic graft-versus-host disease manifestations on major outcomes: a chronic graft-versus-host disease consortium study. Biol Blood Marrow Transplant 2013; 19: 784-791. [original work]

46.    Jacobsohn D, Kurland BF, Pidala J, Inamoto Y, Chai X, Palmer JM, Arai S, Arora M, Jagasia M, Cutler C, Martin PJ, Pavletic SZ, Vogelsang G, Lee SJ, Flowers MED. Correlation between NIH composite skin score, patient-reported skin score and outcome: results from the Chronic GVHD Consortium. Blood 2012; 120: 2545-2552. [original work]

47.    Palmer JM, Lee SJ, Chai X, Storer BE, Flowers ME, Shultz KR, Inamoto Y, Cutler C, Pidala J, Arora M, Jacobsohn DA, Carpenter PA, Pavletic SZ, Martin PJ. Poor agreement between clinician response ratings and calculated response measures in patients with chronic graft-versus-host disease. Biol Blood Marrow Transplant 2012; 18: 1649-1655. [original work]

48.    Pidala J, Vogelsang G, Martin P, Chai X, Storer B, Pavletic S, Weisdorf DJ, Jagasia M, Jacobsohn D, Palmer J, Lee SJ. Overlap subtype of chronic graft-versus-host disease is associated with an adverse prognosis, functional impairment, and inferior patient reported outcomes: a chronic graft-versus-host disease consortium study. Haematologica 2012; 97: 451-458. [original work]

49.    Inamoto Y, Chai X, Kurland BF, Cutler C, Flowers ME, Palmer JM, Carpenter PA, Heffernan MJ, Jacobsohn D, Jagasia MH, Pidala J, Khera N, Vogelsang GB, Weisdorf D, Martin PJ, Pavletic SZ, Lee SJ; Chronic GVHD Consortium. Validation of measurement scales in ocular graft-versus-host disease. Ophthalmology 2012; 119: 487-493. [original work]

50.    Arai S, Jagasia M, Storer B, Chai X, Pidala J, Cutler C, Arora M, Weisdorf DJ, Flowers ME, Martin PJ, Palmer J, Jacobsohn D, Pavletic SZ, Vogelsang GB, Lee SJ. Global and organ-specific chronic graft-versus-host disease severity according to the 2005 NIH Consensus Criteria. Blood 2011; 118: 4242-4249. [original work]

51.    Pidala J, Kurland BF, Chai X, Vogelsang G, Weisdorf DJ, Pavletic S, Cutler C, Majhail N, Lee SJ. Sensitivity of changes in chronic graft-versus-host disease activity to changes in patient-reported quality of life: results from the Chronic Graft-Host Disease Consortium. Haematologica 2011; 96: 1528-1535. [original work]

52.    Rationale and design of the Chronic GVHD cohort study: improving outcomes assessment in chronic GVHD. Biol Blood Marrow Transplant 2011; 17: 1114-1120. [review]

53.    Pidala J, Kurland B, Chai X, Majhail N, Weisdorf DJ, Pavletic S, Cutler C, Jacobsohn D, Palmer J, Arai S, Jagasia M, Lee SJ. Patient-reported quality of life is associated with severity of chronic graft-versus-host disease as measured by NIH criteria: report on baseline data from the Chronic GVHD Consortium. Blood 2011, 117: 4651-4657. [original work]